Suntinorexton () is an experimental orexin receptor agonist. It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company. It is being evaluated for the treatment of narcolepsy.
See also Orexin receptor § Agonists List of investigational narcolepsy and hypersomnia drugs
References